CD163 and head and neck squamous cell carcinoma: Recently, overexpression of M2-like CD163+ TAMs in head and neck squamous cell carcinoma (HNSCC) patients, revealed a poor clinical prognosis in both overall survival (OS) and progression-free survival (PFS) (26).